Gracell Biotechnologies to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

Rhea-AI Summary

Gracell Biotechnologies Inc. (NASDAQ: GRCL) announced its plan to release unaudited financial results for Q1 2022 on May 16, 2022, before U.S. market opening. The company will also provide updates on recent developments during a live conference call at 8:00 AM ET. Gracell focuses on developing affordable cell therapies to treat cancer, utilizing its innovative technology platforms, including FasTCAR and TruUCAR. The company aims to address challenges in conventional CAR-T therapies.

Positive

• Gracell is set to present Q1 2022 financial results, indicating potential transparency and accountability.
• The company is advancing its clinical-stage pipeline, focusing on overcoming challenges in CAR-T therapies through innovation.

Negative

• None.

SAN DIEGO, Calif., and SUZHOU, China, May 02, 2022 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced that it plans to release unaudited financial results for the first quarter ended March 31, 2022 and provide an update on recent developments prior to the open of the U.S. financial markets on Monday, May 16, 2022. The management team will host a live audio webcast and conference call at 8:00 AM Eastern Time.

Conference call and webcast details:

Monday, May 16, 2022 @ 8:00am ET
Investor domestic dial-in: (833) 693-0545
Investor international dial-in: (661) 407-1586
Conference ID: 2093503
Live webcast link: https://ir.gracellbio.com/news-events/events-and-presentations

A replay of the webcast will be available on ir.gracellbio.com shortly after the conclusion of the event for 90 days.

About Gracell
Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. Leveraging its pioneering FasTCAR and TruUCAR technology platforms and SMART CART^TM technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost and lack of effective CAR-T therapies for solid tumors. For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

Media contact
Marvin Tang
marvin.tang@gracellbio.com
Kyle Evans
kyle.evans@westwicke.com

Investor Contact
Gracie Tong
Gracie.tong@gracellbio.com
Stephanie Carrington
Stephanie.carrington@westwicke.com

FAQ

When will Gracell Biotechnologies release its Q1 2022 financial results?

Gracell Biotechnologies plans to release its unaudited financial results for Q1 2022 on May 16, 2022.

What time is the Gracell Biotechnologies conference call for Q1 2022 results?

The conference call for Gracell's Q1 2022 results will be held at 8:00 AM ET on May 16, 2022.

What technologies is Gracell Biotechnologies developing?

Gracell is developing cell therapies using its FasTCAR and TruUCAR technology platforms aimed at improving CAR-T therapy effectiveness.

What is the purpose of Gracell's upcoming financial release?

The upcoming financial release aims to update investors on Q1 2022 results and recent company developments.